NTP HIGH THROUGHPUT SCREENING FOR IMMUNOTOXICOLOGY WITH VENDOR HEMOGENIX, INC.,

使用供应商 HEMOGENIX, INC. 进行免疫毒理学 NTP 高通量筛选

• 批准号: 7936482
• 负责人: KAREN HALL
• 金额: $ 15.4万
• 依托单位: HEMOGENIX, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-13 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7936482
• 关键词: NTP; THROUGHPUT; SCREENING; IMMUNOTOXICOLOGY; VENDOR

This project is in support of the NTP¿s High Throughput Screening Program goals which call for the use of novel in vitro approaches to characterize patterns of toxicity for environmentally important chemicals and to develop toxicity signatures for these chemicals for use in triaging chemicals for detailed follow-up testing and ultimately, for predicting in vivo toxicity. One of the toxicity disciplines for which NTP has sought testing applications is Immunotoxicity. To this end, twenty-five model compounds, selected because of interest by NTP scientists in their potential for immunotoxicity, will be tested on 5 lympho-hematopoietic cell populations (a mixture of lympho-hematopoietic stem, progenitor, and precursor cells) from 3 species (human, rat, and mouse) at 6 doses per compound using 6 replicates per dose. The study will be performed using the HALO¿ - 384 HT Platform, developed and validated by Hemogenix, Inc. Cells from the 3 species of interest will be procured by Hemogenix, Inc., and processed for use in this immunotoxicity screening project. The 25 compounds to be tested for immunotoxicity will be provided by NTP and formulated according to requirements specified by Hemogenix (stock concentration, vehicle, coding information, etc). Hemogenix, Inc., will make the appropriate serial dosing dilutions from the stock solutions provided by NTP. Human cells will be incubated for 5 days with test compounds; rat and mouse cells will be incubated for 4 days. Hemogenix, Inc., will collect the resulting data and prepare a final project report detailing the results of the study.

该项目支持NTP的高通量筛选计划目标，该目标要求使用新的体外方法来表征对环境重要的化学品的毒性模式，并为这些化学品开发毒性特征，用于分类化学品进行详细的后续测试，并最终预测体内毒性。 NTP寻求测试应用的毒性学科之一是免疫毒性。 为此，选择了25种模型化合物，因为NTP科学家对它们的免疫毒性潜力感兴趣，将在来自3个物种（人、大鼠和小鼠）的5个淋巴造血细胞群（淋巴造血干细胞、祖细胞和前体细胞的混合物）上进行测试，每种化合物6个剂量，每个剂量重复6次。 本研究将使用由Hemogenix，Inc.开发和确认的HALO <$- 384 HT平台进行。来自3个感兴趣种属的细胞将由Hemogenix，Inc.采购，并加工用于免疫毒性筛选项目。 待检测免疫毒性的25种化合物将由NTP提供，并根据Hemogenix规定的要求（贮备液浓度、溶剂、编码信息等）配制。 Hemogenix，Inc.，将从NTP提供的贮备液中制备适当的连续给药稀释液。 人细胞将与供试化合物一起孵育5天;大鼠和小鼠细胞将孵育4天。Hemogenix，Inc.，将收集由此产生的数据，并编写一份详细说明研究结果的最后项目报告。